Drug:
Reaction: ACCIDENTAL EXPOSURE TO PRODUCT
20250101 - 20251231
No. 701 - 800
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 701 | 25053517 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 702 | 25053518 |
US |
45 | 2 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 703 | 25053567 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 704 | 25053595 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, Injection site pain, |
||||
DUPILUMAB, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 705 | 25053626 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 706 | 25053641 |
US |
59 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 707 | 25053644 |
US |
45 | 1 |
Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 708 | 25053658 |
US |
76 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 709 | 25053671 |
US |
53 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 710 | 25053723 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 711 | 25053726 |
US |
80 | 2 |
Injection site pruritus, Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, LATANOPROST, VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE, LEVOTHYROXINE, LOSARTAN POTASSIUM, LOSARTAN, AMLODIPINE BESYLATE, HYDROCHLOROTHIAZIDE, BRIMONIDINE, BRIMONIDINE TARTRATE, ALENDRONATE SODIUM, ALENDRONATE SODIUM TABLET, TIMOLOL MALEATE, TIMOLOL MALEATE OPHTHALMIC, DORZOLAMIDE, |
||||
| 712 | 25053740 |
US |
79 | 1 |
Injection site erythema, Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, CERTOLIZUMAB PEGOL, RUXOLITINIB, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, DICLOFENAC SODIUM AND MISOPROSTOL, ERGOCALCIFEROL, SOLIFENACIN SUCCINATE, FISH OIL, VITAMIN A, METHOTREXATE, METHOTREXATE SODIUM, FINASTERIDE, TAMSULOSIN HYDROCHLORIDE, BUPROPION HYDROCHLORIDE, LOSARTAN POTASSIUM, LOSARTAN, |
||||
| 713 | 25053761 |
US |
79 | 1 |
Injection site erythema, Exposure via skin contact, Accidental exposure to product, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, CERTOLIZUMAB PEGOL, RUXOLITINIB, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, DICLOFENAC SODIUM AND MISOPROSTOL, ERGOCALCIFEROL, SOLIFENACIN SUCCINATE, FISH OIL, VITAMIN A, METHOTREXATE, METHOTREXATE SODIUM, FINASTERIDE, TAMSULOSIN HYDROCHLORIDE, BUPROPION HYDROCHLORIDE, LOSARTAN POTASSIUM, LOSARTAN, |
||||
| 714 | 25053805 |
US |
2 | |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 715 | 25053830 |
US |
69 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 716 | 25053835 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 717 | 25053912 |
US |
55 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 718 | 25053946 |
US |
85 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 719 | 25053957 |
US |
74 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 720 | 25053990 |
US |
61 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 721 | 25053999 |
US |
51 | 2 |
Tooth discolouration, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, INSULIN LISPRO, KETOROLAC TROMETHAMINE, LATANOPROST, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, OFLOXACIN, OFLOXACIN OTIC, OFLOXACIN OPHTHALMIC SOLUTION USP, 0.3%, OFLOXACIN OTIC SOLUTION, POLYETHYLENE GLYCOL-3350 AND ELECTROLYTES WITH FLAVOR PACK, BRIMONIDINE TARTRATE, BRINZOLAMIDE, |
||||
| 722 | 25054059 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 723 | 25054109 |
US |
63 | 1 |
Off label use, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE AND LIXISENATIDE, |
||||
| 724 | 25054150 |
US |
55 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 725 | 25054171 |
US |
14 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 726 | 25054181 |
US |
71 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 727 | 25054213 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 728 | 25054255 |
US |
32 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 729 | 25054318 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 730 | 25054344 |
US |
52 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 731 | 25054364 |
US |
73 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE AND LIXISENATIDE, |
||||
| 732 | 25054440 |
US |
72 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE AND LIXISENATIDE, |
||||
| 733 | 25054479 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 734 | 25054485 |
US |
39 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 735 | 25054492 |
US |
50 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 736 | 25044682 |
US |
66 | 2 |
Injury corneal, Accidental exposure to product, Exposure via skin contact, Circumstance or information capable of leading to medication error, Wrong technique in product usage process, |
||||
PERFLUOROHEXYLOCTANE, |
||||
| 737 | 25045148 |
US |
85 | 2 |
Incorrect dose administered, Accidental exposure to product, |
||||
MEPOLIZUMAB, |
||||
| 738 | 25045275 |
US |
57 | 1 |
Product preparation error, Device difficult to use, Accidental exposure to product, Incorrect dose administered by device, Incorrect disposal of product, Injection site pain, Injection site streaking, |
||||
EVOLOCUMAB, |
||||
| 739 | 25045712 |
CN |
||
Accidental exposure to product, Needle issue, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 740 | 25045748 |
US |
56 | 2 |
Coronary artery occlusion, Device difficult to use, Device use error, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 741 | 25045968 |
US |
18 | 2 |
Injection site pain, Injection site erythema, Injection site bruising, Accidental exposure to product, Exposure via skin contact, Off label use, |
||||
ADALIMUMAB-BWWD, LEVOTHYROXINE SODIUM, |
||||
| 742 | 25046062 |
US |
1 | |
Device leakage, Drug dose omission by device, Accidental exposure to product, Device defective, |
||||
SECUKINUMAB, |
||||
| 743 | 25046173 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
SOMATROPIN, |
||||
| 744 | 25047806 |
US |
1 | |
Device malfunction, Needle issue, Accidental exposure to product, Device leakage, |
||||
OFATUMUMAB, |
||||
| 745 | 25047837 |
US |
2 | |
Accidental exposure to product, Injury associated with device, Device malfunction, |
||||
ENOXAPARIN SODIUM, |
||||
| 746 | 25048096 |
CA |
64 | |
Injection site pain, Incorrect dose administered by device, Device leakage, Accidental exposure to product, Syncope, |
||||
TIOTROPIUM BROMIDE, ALBUTEROL SULFATE, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, |
||||
| 747 | 25039148 |
US |
47 | 2 |
Exposure via skin contact, Pain, Wrong technique in device usage process, Underdose, Accidental exposure to product, Product use in unapproved indication, |
||||
BELIMUMAB, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, HYDROXYCHLOROQUINE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PREDNISONE, |
||||
| 748 | 25039213 |
US |
75 | 1 |
Accidental exposure to product, Blood cholesterol decreased, |
||||
EVOLOCUMAB, |
||||
| 749 | 25039337 |
US |
37 | 2 |
Accidental exposure to product, Device difficult to use, Drug dose omission by device, Wrong technique in product usage process, Injection site indentation, |
||||
EVOLOCUMAB, |
||||
| 750 | 25039419 |
US |
60 | 2 |
Device malfunction, Accidental exposure to product, Injection site indentation, |
||||
FREMANEZUMAB-VFRM, |
||||
| 751 | 25039432 |
US |
41 | 2 |
Influenza, Accidental exposure to product, Wrong technique in device usage process, Product dose omission issue, Device issue, |
||||
FREMANEZUMAB-VFRM, |
||||
| 752 | 25039635 |
US |
41 | 2 |
Fear of injection, Accidental exposure to product, |
||||
FREMANEZUMAB-VFRM, |
||||
| 753 | 25039658 |
US |
2 | |
Product dose omission issue, Needle issue, Product leakage, Accidental exposure to product, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 754 | 25040128 |
US |
74 | 2 |
Injection site pain, Exposure via skin contact, Product dose omission issue, Accidental exposure to product, |
||||
MEPOLIZUMAB, |
||||
| 755 | 25040140 |
US |
58 | 2 |
Device difficult to use, Accidental exposure to product, Injection site pain, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 756 | 25040640 |
US |
83 | 1 |
Dizziness, Device difficult to use, Accidental exposure to product, Therapy interrupted, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 757 | 25040908 |
US |
5 | 2 |
Off label use, Device issue, Accidental exposure to product, Product dose omission issue, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 758 | 25041265 |
US |
18 | 2 |
Injection site swelling, Injection site pain, Accidental exposure to product, Drug dose omission by device, Device difficult to use, Injury associated with device, |
||||
ERENUMAB-AOOE, DULOXETINE HYDROCHLORIDE, DULOXETINE, PROPRANOLOL HYDROCHLORIDE, EPINEPHRINE, |
||||
| 759 | 25041452 |
US |
59 | 2 |
Device malfunction, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 760 | 25041483 |
US |
1 | |
Accidental exposure to product, Device leakage, Exposure via skin contact, Device delivery system issue, Device defective, |
||||
OFATUMUMAB, |
||||
| 761 | 25042876 |
US |
2 | |
Accidental exposure to product, Device leakage, |
||||
OFATUMUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, |
||||
| 762 | 25042918 |
US |
2 | |
Device defective, Accidental exposure to product, Drug dose omission by device, Device leakage, |
||||
SECUKINUMAB, TIRZEPATIDE, DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE, DULOXETINE, LISINOPRIL, ERGOCALCIFEROL, |
||||
| 763 | 25043370 |
CA |
29 | 2 |
Accidental exposure to product, Dyspnoea, Anaphylactic reaction, Blood pressure fluctuation, Chest discomfort, Cough, Drug hypersensitivity, Gastroenteritis viral, Heart rate abnormal, Hyperhidrosis, Inappropriate schedule of product administration, Injection site urticaria, Migraine, Nasopharyngitis, Nausea, Oropharyngeal pain, Rhinorrhoea, Throat irritation, Urticaria, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, CHLORPHENIRAMINE MALEATE, EPINEPHRINE, ADRENALINUM, |
||||
| 764 | 25034049 |
US |
52 | 2 |
Accidental exposure to product, Headache, Device malfunction, |
||||
FREMANEZUMAB-VFRM, |
||||
| 765 | 25034140 |
US |
17 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 766 | 25034274 |
US |
2 | |
Device deployment issue, Accidental exposure to product, Exposure via skin contact, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 767 | 25034284 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 768 | 25034332 |
US |
27 | 1 |
Device malfunction, Needle issue, Accidental exposure to product, Device defective, Product dose omission issue, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 769 | 25034396 |
US |
71 | 2 |
Foot fracture, Accidental exposure to product, Device difficult to use, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 770 | 25034524 |
US |
||
Device malfunction, Exposure via skin contact, Accidental exposure to product, Intentional product use issue, |
||||
ADALIMUMAB, ADALIMUMAB, |
||||
| 771 | 25034561 |
US |
||
Device defective, Exposure via skin contact, Accidental exposure to product, |
||||
ADALIMUMAB, |
||||
| 772 | 25034572 |
US |
||
Product leakage, Product distribution issue, Accidental exposure to product, Exposure via skin contact, Product dose omission issue, |
||||
ADALIMUMAB, |
||||
| 773 | 25034656 |
US |
||
Injury associated with device, Drug delivery system malfunction, Accidental exposure to product, Intentional product use issue, |
||||
ADALIMUMAB, ADALIMUMAB, CETIRIZINE HYDROCHLORIDE, METHOTREXATE, METHOTREXATE SODIUM, FOLIC ACID, |
||||
| 774 | 25034675 |
US |
||
Exposure via skin contact, Accidental exposure to product, Incorrect dose administered, |
||||
ADALIMUMAB, |
||||
| 775 | 25034707 |
US |
||
Accidental exposure to product, Wrong patient received product, Wrong technique in device usage process, |
||||
ADALIMUMAB, |
||||
| 776 | 25035070 |
US |
||
Device malfunction, Accidental exposure to product, Exposure via skin contact, |
||||
ADALIMUMAB, |
||||
| 777 | 25035158 |
US |
2 | |
Drug level increased, Accidental exposure to product, Overdose, Encephalopathy, Seizure, Cardiac arrest, Brain death, Shock, |
||||
BUPROPION HYDROCHLORIDE, BUPROPION, |
||||
| 778 | 25035239 |
US |
||
Device use error, Drug dose omission by device, Accidental exposure to product, Device difficult to use, Injury associated with device, |
||||
EVOLOCUMAB, |
||||
| 779 | 25036381 |
US |
71 | 1 |
Accidental exposure to product, Product quality issue, Device failure, Device malfunction, No adverse event, |
||||
OMALIZUMAB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ALBUTEROL SULFATE, ASCORBIC ACID, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, DONEPEZIL HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE, DULOXETIN HYDROCHLORIDE, DULOXETINE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM DELAYED RELEASE CAPSULES, ETODOLAC, FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE ORAL, FEXOFENADINE HCL, MECLIZINE HYDROCHLORIDE, MECLIZINE HCL, MECLIZINE, MEMANTINE, MEMANTINE HYDROCHLORIDE, METHOCARBAMOL, METHOCARBAMOL TABLETS, MOMETASONE FUROATE AND FORMOTEROL FUMARATE DIHYDRATE, NITROGLYCERIN, POLYETHYLENE GLYCOL (3350), POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 400, ERGOCALCIFEROL, BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE (XL), CYANOCOBALAMIN, |
||||
| 780 | 25036705 |
SE |
||
Device deployment issue, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 781 | 25036957 |
US |
||
Incorrect dose administered by device, Exposure via skin contact, Accidental exposure to product, Device use error, |
||||
ADALIMUMAB-ADAZ, |
||||
| 782 | 25037411 |
US |
64 | 2 |
Therapy interrupted, Device difficult to use, Accidental exposure to product, Device use error, Arthritis, Product communication issue, |
||||
ETANERCEPT, ETANERCEPT, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 783 | 25037660 |
FR |
28 | 2 |
Product dose omission issue, Accidental exposure to product, Device deployment issue, |
||||
GOLIMUMAB, |
||||
| 784 | 25037725 |
US |
38 | 2 |
Device issue, Accidental exposure to product, Product dose omission issue, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 785 | 25037808 |
CO |
2 | |
Exposure via skin contact, Accidental exposure to product, Product communication issue, Wrong technique in device usage process, Device breakage, Device leakage, |
||||
SOMATROPIN, |
||||
| 786 | 25037846 |
US |
58 | 2 |
Device difficult to use, Injury associated with device, Accidental exposure to product, Drug dose omission by device, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 787 | 25037910 |
US |
50 | 2 |
Device leakage, Product dose omission issue, Accidental exposure to product, |
||||
GUSELKUMAB, GUSELKUMAB, |
||||
| 788 | 25038222 |
US |
1 | |
Wrong patient received product, Wrong technique in product usage process, Device leakage, Accidental exposure to product, |
||||
OFATUMUMAB, LEVOTHYROXINE, PROGESTERONE, |
||||
| 789 | 25029331 |
CA |
36 | 2 |
Psoriatic arthropathy, Pain, Pruritus, Hangover, Dyspnoea, Influenza, Pain in extremity, Psoriasis, Musculoskeletal stiffness, Skin disorder, Hypersensitivity, Drug ineffective, Fatigue, Musculoskeletal discomfort, Asthenia, Musculoskeletal chest pain, Accidental exposure to product, Myalgia, Pneumonia, Neck pain, |
||||
DICLOFENAC, DICLOFENAC SODIUM, BECLOMETHASONE DIPROPIONATE, BECLOMETHASONE DIPROPIONATE, CELECOXIB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, FOLIC ACID, METHOTREXATE, METHOTREXATE SODIUM, NAPROXEN, NAPROXEN SODIUM, NAPROXEN, NAPROXEN SODIUM, RAMIPRIL, INFLIXIMAB, GOLIMUMAB, GOLIMUMAB, SULFASALAZINE, SULFASALAZINE, SULINDAC, SULINDAC, |
||||
| 790 | 25029407 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, Device malfunction, Device deployment issue, Device leakage, Device delivery system issue, |
||||
ADALIMUMAB-ADAZ, |
||||
| 791 | 25029514 |
US |
2 | |
Erythema, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 792 | 25029564 |
US |
49 | 2 |
Accidental exposure to product, Device difficult to use, Wrong technique in product usage process, Drug dose omission by device, Influenza, |
||||
ERENUMAB-AOOE, |
||||
| 793 | 25029585 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 794 | 25029600 |
US |
26 | 2 |
Eczema, Pruritus, Erythema, Swelling, Rash, Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 795 | 25029739 |
US |
1 | |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 796 | 25029922 |
US |
77 | 2 |
Cough, Dyspnoea, Rhinorrhoea, Wheezing, Chest discomfort, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 797 | 25029925 |
US |
77 | 2 |
Injection site discharge, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, MONTELUKAST SODIUM, MONTELUKAST, ACETAMINOPHEN, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, CETIRIZINE HYDROCHLORIDE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, AMLODIPINE BESYLATE, ERGOCALCIFEROL, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM, FILM COATED, DICLOFENAC POTASSIUM TABLETS, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, CLONAZEPAM, FREMANEZUMAB-VFRM, IPRATROPIUM BROMIDE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ARIPIPRAZOLE ORALLY DISINTEGRATING, ARIPIPRAZOLE, ARIPIPRAZOLE ORAL, ALBUTEROL SULFATE, FAMOTIDINE, |
||||
| 798 | 25030261 |
US |
28 | 1 |
Needle issue, Accidental exposure to product, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 799 | 25030527 |
US |
59 | |
Injection site haemorrhage, Accidental exposure to product, Incorrect disposal of product, Product communication issue, Device difficult to use, Drug dose omission by device, |
||||
EVOLOCUMAB, TIRZEPATIDE, |
||||
| 800 | 25030821 |
US |
25 | 1 |
Device leakage, Injection site pain, Injection site haemorrhage, Accidental exposure to product, |
||||
GUSELKUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28